Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome

Blood

Volumn 118, Issue 17, 2011, Pages 4585-4590

  Savage, Kerry J ^a   Skinnider, Brian ^b   Al Mansour, Mubarak ^a   Sehn, Laurie H ^a   Gascoyne, Randy D ^b   Connors, Joseph M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 80055074730     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-365932     Document Type: Article

References (22)

1. Poppema S, Delsol G, Pileri SA, et al. Nodular lymphocyte predominant Hodgkin lymphoma. In: WHO Classification of Tumors of Haematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 2008.
2. Anagnostopoulos I, Hansmann ML, Franssila K, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000;96(5):1889-1899. (Pubitemid 30661074)
3. Hoppe RT, Advani RH, Ai WZ, et al. NCCN Clinical practice guidelines in oncology: Hodgkin lymphoma. National Comprehensive Cancer Network. www.nccn.org. Accessed June 2011.
4. Horwich A, Specht L, Ashley S. Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer. 1997;33(6):848-853. (Pubitemid 27287034)
5. Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol. 2010;28(5):793-799.
6. Biasoli I, Stamatoullas A, Meignin V, et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer. 2010;116(3):631-639.
7. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (4th ed). Lyon, France: IARC Press; 2008.
8. Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol. 2008;26(32):5170-5174.
9. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003;21(4):607-614. (Pubitemid 46621893)
10. Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocytepredominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer. 2005;104(6):1221-1229. (Pubitemid 41278957)
11. Jackson C, Sirohi B, Cunningham D, Horwich A, Thomas K, Wotherspoon A. Lymphocyte-predominant Hodgkin lymphoma: clinical features and treatment outcomes from a 30-year experience. Ann Oncol. 2010;21(10):2061-2068.
12. Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol. 2010;28(1):136-141.
13. Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2008;26(3):434-439. (Pubitemid 351171696)
14. Feugier P, Labouyrie E, Djeridane M, et al. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood. 2004;104(9):2675-2681. (Pubitemid 39434947)
15. Engert A, Eichenauer DA, Dreyling M. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):168-171.
16. Wilder RB, Schlembach PJ, Jones D, et al. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte: very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer. 2002;94(6):1731-1738. (Pubitemid 34241111)
17. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640-652.
18. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(21):4634-4642. (Pubitemid 46237440)
19. Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma: experience from the European network group on pediatric Hodgkin lymphoma. Cancer. 2007;110(1):179-185. (Pubitemid 46986431)
20. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte predominant Hodgkin's disease: results of a phase II trial. Blood. 2003;101:4285-4289. (Pubitemid 36857790)
21. Horning S, Barlett N, Breslin S, et al. Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD) [abstract]. Blood. 2007;110:644a.
22. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111(1):109-111.